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The strategy of comparative oncology is to find homologous molecules, homologous signaling cascades and homologous immune mechanisms to cure cancer in both humans and pets according to the "One Health" principle \[[@CR1]\]. Similar to humans, dogs spontaneously develop malignancies with comparable incidence and prevalence and hence represent a natural model for human cancer. For instance, a Swedish study on 80,000 insured female dogs reported that, dependent on higher age and breed, up to 13 % of female dogs had at least one mammary tumor, with an overall-case fatality of 6 % \[[@CR2]\]. In humans, females in more highly developed areas have a cumulative risk of 7.1 % of developing mammary cancer by the age of 75, with a mortality rate of 1.7 % \[[@CR3]\]. Mammary carcinoma, among others, is thus a burden in both human and veterinary medicines.

The rationale for favouring this tumor entity for comparative studies derives from the fact that it is wise to have access to primary lesions for monitoring tumor progression by caliper measurements. This facilitates the clinical investigations and also takes into consideration that only few centers have access to imaging facilities. Often more than one mamilla are affected in canine cancer patients and may be compared side by side.

It can further be expected that results from comparative oncology studies, investigating naturally occurring cancers due to distinct risk factors in distinct breeds, have a higher translational potential than studies with genetically highly homologous mouse strains \[[@CR4]\]. For example, the epidermal growth factor receptor (EGFR) family members EGFR (ErbB1) and human epidermal growth factor receptor 2 (HER-2 (ErbB2)) are molecules of outstanding homology between humans and dogs, and targeting of these molecules results in the same effects on signaling and cancer biology in both species \[[@CR5], [@CR6]\].

A more intricate situation was observed for the carcinoembryonic antigen \[CEA, also termed carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)\], which represents a classical soluble as well as membrane-expressed tumor marker in human clinical oncology. Serum levels of soluble human CEA correlate with disease progression \[[@CR7]\], and its assessment is recommended in monitoring the treatment course of colorectal cancer in combination with other prognostic markers \[[@CR8], [@CR9]\]. However, CEA molecules are structurally and evolutionarily diverse between humans and canines \[[@CR10], [@CR11]\]. A direct CEA homolog in dogs has not yet been defined and represents "a missing link" (Table [1](#Tab1){ref-type="table"}). In contrast, overexpression of CEA in humans has been known for over 20 years to play an important role in metastasis and cell motility \[[@CR12]\] by acting as a ligand for E- and L-selectins \[[@CR13]\] and might have a signaling function probably by interacting with the Wnt pathway \[[@CR14]\]. Furthermore, vaccination with an adeno-associated virus (AAV)--CEA vector combined with Toll-like receptor-9 or Toll-like receptor-7 agonists in wild-type mice resulted in enhanced Th1-mediated immunity and protection from challenge with MC38 colon tumor cells expressing CEA, whereas the same CEA vaccines in CEA transgenic animals promoted tumor growth due to tolerance phenomena elicited by dendritic and myeloid cells \[[@CR15]\]. Some CEA family members such as CEACAM6 may adhere to and inhibit tumor-infiltrating cytotoxic T cells \[[@CR16]\]. CEACAM1, CEACAM5 and CEACAM6 may be released from epithelial tumors in microvesicles, whereas tumor endothelia only contain CEACAM1 which has a receptor function for other CEACAMs, influences T cell behavior \[[@CR17]\] and regulates the tumor matrix and microvascularization \[[@CR18]\]. Hence, CEA may affect the tumor and its stroma at the same time \[[@CR19]\].Table 1Interspecies amino acid sequence comparisonsMoleculeHumanCanineSequence identity (%)Sequence similarity (%)CEARHNRPM_HUMANXP_005633012.199.399.5CEA (CEACAM5)CEAM5_HUMANn.d. \[[@CR20]\]----TGF-β-RITGFR1_HUMANF1PS63_CANFA91.892.2TGF-β-RIITGFR2_HUMANF1PNA9_CANFA87.490.3TGF-β-RIIITGBR3_HUMANF1PIG0_CANFA88.693.0TGF-β1TGFB1_HUMANTGFB1-CANFA94.196.7TGF-β2TGFB2_HUMANF1PKH0_CANFA99.599.8TGF-β3TGFB3_HUMANF1PR85_CANFA88.489.5NFκB1NFκB1_HUMANNFκB1_CANFA91.094.2NFκB2NFκB2_HUMANE2RLL2_CANFA92.394.9RelATF65_HUMANF1PCU1_CANFA91.293.5Sequences were from UniProt (<http://www.uniprot.org/uniprot/>) and from the National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/protein>). Sequences were aligned using a Needleman--Wunsch algorithm (<http://www.ebi.ac.uk/Tools/psa/>) with a BLOSUM 62 matrix; gap penalty and end penalty were defined as 10.0 and 0.5, respectively
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The scientific history of the carcinoembryonic antigen receptor (CEAR) is much more recent. Interestingly, CEAR showed an outstanding sequence identity of 99 % between the human and canine species \[[@CR20]\] (Table [1](#Tab1){ref-type="table"}). The great CEA-receptor homology of humans and dogs on the one hand and the lack of a precise canine CEA equivalent on the other hand are discrepancies and indicate that there could be an alternative ligand. The CEAR was originally described in Kupffer cells and identified as the heterogeneous nuclear ribonucleoprotein M4 (hnRNP M4) \[[@CR21]\]. Regarding oncology, it was later also found on colon cancer cells \[[@CR22]\]. Moreover, its expression was subsequently also detected in mice in the entire gastrointestinal tract including liver and pancreas \[[@CR23]\]. CEAR expression has been connected to inflammation in the liver \[[@CR24]\]. In Kupffer cells, a full-length hnRNP M4 (CEARL) and a truncated form (CEARS), generated by alternative splicing, were described \[[@CR14]\]. The minimal structural element of human CEACAM5 interacting with hnRNP M4/CEAR was reduced to a peptide of eight amino acids \[[@CR25]\].

Surprisingly, a recent study has shown that CEA not only signals via its specific receptor, CEAR, but can also bind to the receptor of the important immunomodulatory cytokine transforming growth factor beta (TGF-β, Fig. [1](#Fig1){ref-type="fig"}) \[[@CR26]\].Fig. 1Interconnected networks of CEA and TGF-β signaling in cancer. The cancer cell is an autocrine source of CEA as well as of TGF-β which bind to their specific receptors, CEAR or TGF-β-RI:RII, respectively; the latter signaling via the NFκB pathway. Recently, it has been recognized that CEA also signals via TGF-β-R and initiates the same biological effects \[[@CR26]\]. Additionally, Tregs and Bregs, as well as stroma cells, participate in this network by secreting TGF-β. It remains open whether the reverse is the case, and TGF-β may also interfere with the CEAR pathway, which is much less defined

TGF-β sources and its function in the tumor {#Sec3}
===========================================

Three high-affinity membrane-bound receptors for TGF-β are known so far: type I, type II and type III. The classical TGF-β signaling, however, occurs via the heterotetrameric complex of 2 TGF-β-receptor (TGF-β-R) type I and 2 TGF-β-receptor type II transmembrane receptors with serine/threonine kinase activity \[[@CR27]--[@CR29]\]. In the tumor microenvironment, TGF-β is most typically derived from human and canine Foxp3^+^ regulatory T cells (Tregs). It is well known that Tregs can thereby critically dampen anti-tumor immunity and tolerize cytotoxic T cells \[[@CR30]--[@CR34]\]. More recently, intratumoral regulatory B cells (Bregs) have gained attention in human oncology \[[@CR35], [@CR36]\]. According to Olkhanud et al. \[[@CR37]\], tumor-evoked Bregs should phenotypically resemble activated mature B2 cells (CD19^+^ CD25^hi^ CD69^hi^). Lindner et al. \[[@CR36]\] reported that intratumoral Bregs also express granzyme-B (stimulated by IL-21 from Tregs) and a signature of CD19^+^CD38^+^CD1d^+^IgM^+^CD147^+^, as well as including IL-10, CD25 and indoleamine-2,3-dioxygenase. This population seems interesting as a source of TGF-β and for their capacity to suppress intratumoral CD8^+^ and CD4^+^ effector T cells. Bregs can even convert naïve CD4^+^CD25^−^ T cells to Foxp3^+^ Tregs \[[@CR37]\]. TGF-β, however, may also be derived from tumor stroma cells \[[@CR19], [@CR38]\], where it shapes the microenvironment by interacting with growth factors (epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF) \[[@CR39]\]), cytokines or chemokines, crosstalking to fibroblasts \[[@CR40]\] and supporting the enrichment of endothelial cells, which again shape the extracellular matrix \[[@CR41]\]. TGF-β promotes the loss of epithelial markers such as E-cadherin and the accumulation of the mesenchymal marker vimentin in the process of epithelial--mesenchymal transition (EMT) \[[@CR42]\]. Importantly, in this case tumor stem cells themselves show an enrichment of mesenchymal markers and are a source of TGF-β. Most studies on EMT are done in mouse or human cancer models \[[@CR43]\], but there are reports that EMT transition can be achieved by TGF-β in (normal) Madin--Darby canine kidney (MDCK) cells \[[@CR44]\].

Physiologically, TGF-β acts as a tumor suppressor, negatively regulating cellular proliferation, but this is changed in the cancer microenvironment toward a tumor promoter function, where it mediates proliferation, migration, invasion, EMT and metastasis, associated with high miR-181a expression, and altogether termed the TGF-β-paradox \[[@CR45]\]. In this context, it is important to note that canines are much closer to the human species than murine animal models. The appearance of Tregs also negatively correlates with prognosis in dog cancer patients \[[@CR46]\].

For instance, naive CD4^+^CD25^−^Foxp3^−^ T cells can be converted to Foxp3^+^ Tregs when adoptively transferred into Rag^−/−^ mice only in the presence of TGF-β-positive tumors \[[@CR47]\]. Thus, the intratumoral milieu amplifies the cellular sources for even more immunosuppressive cytokines. It has been recently shown that elevated levels of TGF-β and IL-6 in the tumor microenvironment support Th17 cells and that the resulting inflammation was supporting the clinical development and progression of gastric cancer \[[@CR48]\]. Although Li et al. have shown that CEA binds to TGF-β-R \[[@CR26]\], it has not yet been investigated whether the reverse is true, and TGF-β (besides acting via its own TGF-β-R) may crosstalk via CEAR, thereby imitating the tumor-progressive properties of CEA. CEA modulates effector--target interaction by binding to lymphocytes \[[@CR49]\]. Only CEACAM1 expression was previously described in T cells \[[@CR50]\], whereas the expression of CEACAM5 on T cells was excluded. Regarding this, we are not aware of investigations on the expression of CEAR on T- or B-lymphocytes.

TGF-β signaling {#Sec4}
===============

In contrast to CEAR, the cellular signaling function of which has to the best of our knowledge not yet been reported, the signaling cascade for the TGF-β-R is well known. The nuclear factor kappa-B (NFκB) is a key master regulator in growth and survival \[[@CR51], [@CR52]\]. In normal cells, TGF-β leads to growth inhibition; in short: TGF-β binds to TGF-β-RII, activating TGF-β-RI and then phosphorylating the SMA and MAD homologs SMAD2 and SMAD3, which associate with SMAD4 and together translocate to the nucleus for transcription of genes. All of this is inhibited by SMAD7 \[[@CR53]\]. Interestingly, the TGF-β-R-initiated SMAD pathway was shown to target CEACAM5 (and CEACAM6) genes leading to CEA secretion as a mechanism for proliferation in gastric cancer cells \[[@CR54]\]. It will be interesting in the future to investigate whether a synergistic crosstalk between the CEA and TGF-β signaling cascades in cancer cells exists.

In human head and neck squamous cell carcinoma cell lines, Freudlsperger et al. \[[@CR53]\] could further demonstrate that TGF-β signaling resulted in a sequential phosphorylation of the transforming growth factor-activated kinase-1 (TAK1), inhibitor of nuclear factor kappa-B kinase (IKK), inhibitor of kappa-B subunit alpha (IκBα) and the v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA); however, the crosstalk to CEA was not addressed in this study. Nor did this study address the consecutive activation of TAK1/mitogen-activated protein kinase kinase (MEK)/protein kinase B (AKT)/NFκB and SMAD pathways upon TGF-β stimulation as Gingery et al. \[[@CR55]\] did in osteoclasts.

In human cancers, mutations in the TGF-β pathways (e.g., TGF-β-RII or SMAD4) are frequently observed \[[@CR56]\]. A recent study has indicated that, although most tested colorectal cancer cells displayed an inactivated TGF-β signaling pathway, they actively secreted TGF-β acting on stromal cells and were thus driving metastasis \[[@CR57]\]. In other cancer cell types, TGF-β signaling is intact, but aberrant NFκB activation and NFκB/RelA stimulate proliferation. In this respect, it should be emphasized that NFκB is constitutively activated in a number of hematologic and solid tumors and is one of the major transcription factors associated with cancer progression, inhibition of apoptosis, limitless replicative potential, tissue invasion and metastasis \[[@CR58]\].

The TGF-β-R and NFκB pathways are connected via the TAK-1, which (independently, but parallel to SMAD activation) by phosphorylating IKK can directly stimulate the nuclear factor-κB (NFκB) pathway \[[@CR55]\]. It is tempting to speculate that CEA may induce similar signals by interacting with TGF-β-R \[[@CR26]\]. TAK1 was expressed in head and neck cancers, where nuclear activation of RelA of the NFκB family also took place. TGF-β induced sequential phosphorylation of several targets including TAK1, IKK, IκBα and RelA; additionally, TAK1 again enhanced TGF-β induced NFκB activation \[[@CR53]\]. In human neutrophils, a constitutive association of TAK1 and inhibitor of kappa-B (IκB) was recently reported, indicating a close association of these pathways in inflammatory cells \[[@CR59]\]. Neil et al. could show that the TAK1-binding protein 1 (TAB 1) forms complexes with IκB kinase b (IKKb) resulting in stimulation of the TAK1:IKKb:RelA pathway. The authors concluded that this axis, including the NFκB elements, is pivotal in the oncogenic transformation of breast cancer \[[@CR60]\]. The fact that NFκB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells may additionally complicate the situation \[[@CR61]\].

Conclusion {#Sec5}
==========

Generally, the dog represents an optimal model organism to study cancer biology in a comparative setting, as many genes represent a great degree of homology to their human counterparts \[[@CR62]\]. Even with respect to noncoding RNAs, the significance of similarities between human and dog has recently been acknowledged \[[@CR63]\]. Furthermore, the intriguing amino acid homogeneity among human and canine CEAR, TGF-β and TGF-β-R isoforms, NFκB and RelA are given in Table [1](#Tab1){ref-type="table"}, indicating again an advantage of the dog patient in comparative oncology.

We propose that understanding of the crosstalk between CEA and TGF-β signaling toward NFκB as a key cancer regulator, as well as understanding of the Treg and Breg action in tumor tissue, should be extended, possibly with prognostic value. The dog may be a relevant translational model to study these interactions, in line with the comparative oncology strategy \[[@CR64]\]. In the future, novel drugs may target the Achilles heel of both obviously interconnected networks.
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IGFs

:   Insulin-like growth factors
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:   v-Rel avian reticuloendotheliosis viral oncogene homolog A

SMAD
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